Breast cancer drug that can extend lives approved for NHS use Joy as deal struck to make Kadcyla, which costs an annual £90,000 per patient at full price, available for routine use
A drug that can extend the lives of women with advanced breast cancer has been approved for routine use on the NHS.
Charities and campaigners reacted with huge disappointment when the National Institute for Health and Care Excellence (Nice) rejected the drug, Kadcyla, on cost grounds in 2016. Continue reading... The Guardian
No comments:
Post a Comment